z i m m e r h o l d i n g s , i n c . a n d s u b s i d i a r i e s 2 0 0 4 f o r m 1 0 - k notes to consolidated financial statements ( continued ) the components of accumulated other comprehensive income are as follows ( in millions ) : accumulated foreign foreign minimum unrealized other currency currency pension gains on comprehensive translation hedges liability securities income .
what was the percentage change in accumulated other comprehensive income for 2004?
accounting pronouncements 2013 in november 2004 , the no . 123 ( r ) requires all share-based payments to employees , fasb issued fasb staff position ( 2018 2018fsp 2019 2019 ) 109-1 , 2018 2018application including stock options , to be expensed based on their fair of fasb statement no . 109 , accounting for income taxes , to values . the company has disclosed the effect on net earnings the tax deduction on qualified production activities and earnings per share if the company had applied the fair provided by the american jobs creation act of 2004 2019 2019 and value recognition provisions of sfas 123 . sfas 123 ( r ) fsp 109-2 , 2018 2018accounting and disclosure guidance for the contains three methodologies for adoption : 1 ) adopt foreign earnings repatriation provision within the american sfas 123 ( r ) on the effective date for interim periods jobs creation act of 2004 2019 2019 . fsp 109-1 states that a thereafter , 2 ) adopt sfas 123 ( r ) on the effective date for company 2019s deduction under the american jobs creation act interim periods thereafter and restate prior interim periods of 2004 ( the 2018 2018act 2019 2019 ) should be accounted for as a special included in the fiscal year of adoption under the provisions of deduction in accordance with sfas no . 109 and not as a tax sfas 123 , or 3 ) adopt sfas 123 ( r ) on the effective date for rate reduction . fsp 109-2 provides accounting and disclosure interim periods thereafter and restate all prior interim guidance for repatriation provisions included under the act . periods under the provisions of sfas 123 . the company has fsp 109-1 and fsp 109-2 were both effective upon issuance . not determined an adoption methodology . the company is in the adoption of these fsp 2019s did not have a material impact the process of assessing the impact that sfas 123 ( r ) will on the company 2019s financial position , results of operations or have on its financial position , results of operations and cash cash flows in 2004 . flows . sfas 123 ( r ) is effective for the company on july 1 , in november 2004 , the fasb issued sfas no . 151 , 2005 . 2018 2018inventory costs 2019 2019 to clarify the accounting for abnormal amounts of idle facility expense . sfas no . 151 requires that 3 . acquisitions fixed overhead production costs be applied to inventory at centerpulse ag and incentive capital ag 2018 2018normal capacity 2019 2019 and any excess fixed overhead production costs be charged to expense in the period in which they were on october 2 , 2003 ( the 2018 2018closing date 2019 2019 ) , the company incurred . sfas no . 151 is effective for fiscal years beginning closed its exchange offer for centerpulse , a global after june 15 , 2005 . the company does not expect sfas orthopaedic medical device company headquartered in no . 151 to have a material impact on its financial position , switzerland that services the reconstructive joint , spine and results of operations , or cash flows . dental implant markets . the company also closed its in december 2004 , the fasb issued sfas no . 153 , exchange offer for incentive , a company that , at the closing 2018 2018exchanges of nonmonetary assets 2019 2019 , which is effective for date , owned only cash and beneficially owned 18.3 percent of fiscal years beginning after june 15 , 2004 . the company does the issued centerpulse shares . the primary reason for not routinely engage in exchanges of nonmonetary assets ; as making the centerpulse and incentive exchange offers ( the such , sfas no . 153 is not expected to have a material impact 2018 2018exchange offers 2019 2019 ) was to create a global leader in the on the company 2019s financial position , results of operations or design , development , manufacture and marketing of cash flows . orthopaedic reconstructive implants , including joint and in may 2004 , the fasb issued fsp 106-2 2018 2018accounting dental , spine implants , and trauma products . the strategic and disclosure requirements related to the medicare compatibility of the products and technologies of the prescription drug , improvement and modernization act of company and centerpulse is expected to provide significant 2003 2019 2019 , which is effective for the first interim or annual period earnings power and a strong platform from which it can beginning after june 15 , 2004 . the company does not expect actively pursue growth opportunities in the industry . for the to be eligible for the federal subsidy available pursuant to the company , centerpulse provides a unique platform for growth medicare prescription drug improvement and modernization and diversification in europe as well as in the spine and act of 2003 ; therefore , this staff position did not have a dental areas of the medical device industry . as a result of the material impact on the company 2019s results of operations , exchange offers , the company beneficially owned financial position or cash flow . 98.7 percent of the issued centerpulse shares ( including the in december 2004 , the fasb issued sfas no . 123 ( r ) , centerpulse shares owned by incentive ) and 99.9 percent of 2018 2018share-based payment 2019 2019 , which is a revision to sfas no . 123 , the issued incentive shares on the closing date . 2018 2018accounting for stock based compensation 2019 2019 . sfas .